Free Trial
NASDAQ:MBRX

Moleculin Biotech Q2 2025 Earnings Report

Moleculin Biotech logo
$0.61 +0.06 (+11.33%)
Closing price 04:00 PM Eastern
Extended Trading
$0.57 -0.04 (-6.64%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moleculin Biotech EPS Results

Actual EPS
-$0.49
Consensus EPS
-$0.39
Beat/Miss
Missed by -$0.10
One Year Ago EPS
N/A

Moleculin Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Moleculin Biotech Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, August 13, 2025
Conference Call Time
8:00AM ET

Upcoming Earnings

Moleculin Biotech's Q3 2025 earnings is scheduled for Friday, November 14, 2025, with a conference call scheduled on Wednesday, November 12, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Moleculin Biotech Earnings Headlines

Moleculin Issues New Positive AML Overall Survival Data:
3 Dirt-Cheap Stocks You Can’t Afford to Ignore
Often, investors will overlook stocks just because they're cheap. It's a common thought that a cheap price tag means that something must be wrong with the company. But this couldn't be further from the case in many instances.tc pixel
HC Wainwright Analysts Raise Earnings Estimates for MBRX
See More Moleculin Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Moleculin Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Moleculin Biotech and other key companies, straight to your email.

About Moleculin Biotech

Moleculin Biotech (NASDAQ:MBRX), a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

View Moleculin Biotech Profile

More Earnings Resources from MarketBeat